Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 331 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Observational data collection. Clear all

Conditions: Inflammatory Breast Carcinoma, Invasive Breast Carcinoma, Second Primary Malignant Neoplasm
Interventions: Biospecimen Collection, Interview, Medical Chart Review, Questionnaire Administration; Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2030
U.S. locations: 10
States / cities: Gilbert, Arizona • La Jolla, California • Greeley, Colorado + 6 more

Conditions: Blood Pressure
Interventions: NIRS Monitoring; Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 6 Months
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Workflow, Nursing
Interventions: RTLS current tag, RTLS tag revised; Device
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Beta Lactam Allergy in Patients With a Hematologic Malignancy
Interventions: Semi-structured interview, Survey, Ethnographic observation; Behavioral
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypoxemia, Pulse Oximetry, Skin Pigment
Interventions: Observational; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 757 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Tofersen; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cervical Carcinoma, Human Papillomavirus Infection
Interventions: HPV Self-Collection, Interview, Survey Administration; Procedure · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 25 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Growth Hormone Disorder, Pituitary Dwarfism, Hypopituitarism
Interventions: somatropin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Up to 18 Years
Enrollment: 22,960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2016
U.S. locations: 1
States / cities: Plainsboro, New Jersey

Conditions: Kidney Transplantation
Interventions: Tofacitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 23
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 16 more

Conditions: Sepsis, Burn Injury, Wound Healing, Critical Illness, Multiple Organ Dysfunction Syndrome
Interventions: Observational Cohort (No Intervention); Other
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Tampa, Florida • Atlanta, Georgia • Houston, Texas

Conditions: Persistent Atrial Fibrillation
Interventions: Persistent AF ablation assisted with the STAR Apollo Mapping System; Other
Lead sponsor: Kansas City Heart Rhythm Research Foundation; Other
Eligibility: 18 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 4
States / cities: Jonesboro, Arkansas • Sarasota, Florida • Overland Park, Kansas

Conditions: Focal Segmental Glomerulosclerosis, Minimal Change Disease, FSGS, MCD
Interventions: Biospecimen collection, Data collection; Other
Lead sponsor: University of Michigan; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Carbon Monoxide Intoxication
Interventions: Observational data collection.; Device
Lead sponsor: Nonin Medical, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: COVID-19, Long Haul
Interventions: Ritonavir-Boosted Nirmatrelvir (Paxlovid), Physiological Evaluation, Moderna COVID-19 Vaccine, Biopsychological, Behavioral (e.g., Psychotherapy, Lifestyle Counseling), Genetic (including gene transfer, stem cell and recombinant DNA), Multidisciplinary approach; Drug · Diagnostic Test · Biological + 3 more
Lead sponsor: Well- Konnect Healthcare Services and Research Firm; Network
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hereditary Angioedema (HAE)
Interventions: Not listed
Lead sponsor: Shire; Industry
Eligibility: Not listed
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 23
States / cities: Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 20 more

Conditions: No Applicable Condition; Study of Physiologic Monitor Alarms
Interventions: Observational with data collected; Other
Lead sponsor: Spectrum Ergonomics and Occupational Health Services; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Williamsport, Pennsylvania

Conditions: Psoriasis
Interventions: Observational (Non-Interventional) Registry; Other
Lead sponsor: CorEvitas; Network
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2035
U.S. locations: 1
States / cities: Waltham, Massachusetts

Conditions: Asthma
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Extensive-stage Small-cell Lung Cancer
Interventions: Zepzelca; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 32
States / cities: Huntsville, Alabama • Norwich, Connecticut • Brooksville, Florida + 29 more

Conditions: Bronchopulmonary Dysplasia
Interventions: Tobramycin solution for inhalation 78mg dose, Tobramycin solution for inhalation 150mg dose, Tobramycin solution for inhalation 216mg dose, Tobramycin solution for inhalation 300mg dose; Drug
Lead sponsor: Erik Allen Jensen; Other
Eligibility: 4 Weeks and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Critical Care, Palliative Care
Interventions: Ventilator withdrawal algorithm; Procedure
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 5
States / cities: Detroit, Michigan • Royal Oak, Michigan • Southfield, Michigan

Conditions: Cancer
Interventions: Blood Sample, Surveys; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer, Brain Tumor, Glioblastoma, Astrocytoma, Bile Duct Cancer, Cholangiocarcinoma, Bladder Cancer, Bone Cancer, Synovial Sarcoma, Chondrosarcoma, Liposarcoma, Sarcoma, Kaposi, Sarcoma,Soft Tissue, Sarcoma, Osteosarcoma, CNS Cancer, Brain Stem Neoplasms, Breast Cancer, Cervical Cancer, Colorectal Cancer, Rectal Cancer, Colon Cancer, Esophageal Cancer, Esophagus Cancer, Cancer of Colon, Pancreatic Cancer, Cancer of Pancreas, Testis Cancer, Testicular Cancer, Ureter Cancer, Renal Cell Carcinoma, Kidney Cancer, Gestational Trophoblastic Tumor, Head and Neck Neoplasms, Parotid Tumor, Larynx Cancer, Tongue Cancer, Pharynx Cancer, Salivary Gland Cancer, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma, Carcinoid Tumor, Lung Cancer, Neuroendocrine Tumors, Mesothelioma, Thyroid Cancer, Parathyroid Neoplasms, Adrenal Cancer, Small Bowel Cancer, Stomach Cancer, Liver Cancer, Hepatic Cancer, Melanoma, Skin Cancer, Unknown Primary Tumors, Uterine Cancer, Fallopian Tube Cancer, Ovarian Cancer, Prostate Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Waldenstrom Macroglobulinemia, Cancer, Advanced, Thymus Cancer, Nasopharyngeal Carcinoma, Multiple Endocrine Neoplasia, Pheochromocytoma, Small Cell Carcinoma, Pulmonary Carcinoma
Interventions: Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P); Diagnostic Test · Drug · Other
Lead sponsor: Taproot Health; Industry
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Idaho Falls, Idaho • Laredo, Texas

Conditions: HIV Infections
Interventions: Questionnaire; Behavioral
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2014
U.S. locations: 2
States / cities: Boston, Massachusetts

Search by objective public record fields.

Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer

The Newborn Project: Examining the Oxygenation of Brain Tissue During General Anesthesia

RTLS for Healthcare Process Validation

Allergy Delabeling in Antibiotic Stewardship - Evaluations

Pulse Oximetry Errors in Hospitalized Patients Across Varying Skin Pigmentation

A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)

Evaluating the Human Papillomavirus Self-Collection Experience in Individuals Who Have Experienced Sexual Trauma

An Observational Study (Registry) Assessing Treatment Outcomes and Safety for Children and Adults Who Are Prescribed Norditropin® (Human Growth Hormone)

Collection of Follow-up Data From CP-690,550-treated Kidney Transplant Recipients

Surgical Critical Care Initiative (SC2i) Tissue and Data Acquisition Protocol (TDAP) in Burn Patients Improving the Robustness and Generalizability of Post-burn Sepsis Prediction With the Post-Burn Sepsis Digital Twin. Group 1

Observational Study to Examine the Procedural and Outcomes of AF Ablation Assisted by STAR Apollo™ Mapping System

Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease

Suspected Cases of Carbon Monoxide Poisoning

Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.

A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America

Novel Self-charging, Medical-Grade Smart Insoles With AI/ML Edge Computing to Monitor Biometrics.

PPD™ CorEvitas™ Psoriasis (PSO) Rapid Response Non-Interventional Study

Longitudinal Observational Study of Severe Asthma

To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)

Inhaled Tobramycin in BPD

An Algorithmic Approach to Ventilator Withdrawal at the End of Life

Multi-Cancer Detection Observational Cohort Study

The Registry of Oncology Outcomes Associated With Testing and Treatment

An Observational Study of People Who Have Recently Been Infected With HIV